畸胎瘤细胞源性生长因子对雌激素受体阴性乳腺癌细胞雌激素依赖性的影响被引量：1

Effect of PC-cell derived growth factor shRNA on estrogen dependent of estrogen receptor nagative breast cancer cell lines

原文传递

导出

摘要目的分析乳腺癌细胞雌激素依赖性与畸胎瘤细胞源性生长因子(PC-cell derivedgrowth factor,PCDGF)表达之间的关系,探讨雌激素受体(ER)阴性乳腺癌患者接受内分泌治疗的可能性。方法荧光定量聚合酶链反应检测乳腺癌细胞系 MCF-7、MDA-MB-231、T47D、MDA-MB-435s中 PCDGF 的表达,CCK-8法检测不同浓度雌激素培养条件下细胞的存活情况。以 ER 阳性乳腺癌细胞系 MCF-7为对照,用 RNA 干扰技术抑制 ER 阴性乳腺癌细胞系 MDA-MB-231中 PCDGF 基因的表达,观察抑制前后雌激素依赖性的变化。结果 PCDGF 在4株乳腺癌细胞系中均有不同程度的表达,其中在 MDA-MB-435s 中表达量最高,PCDGF 高表达的乳腺癌细胞系的雌激素依赖性较高,PCDGF shRNA 可以有效抑制乳腺癌细胞系 MCF-7和 MDA-MB-213中 PCDGF 的表达(抑制率分别为81.1%和86.7%)。MDA-MB-231细胞系雌激素依赖性增加的程度高于 MCF-7细胞系(P<0.05)。结论 PCDGF 高表达于 ER 阴性乳腺癌细胞,抑制其表达可能会更好的逆转内分泌治疗的耐药性。 Objective To analyze the relationship between estrogen dependence of breast cancer cells and expression level of PC-cell derived growth factor （ PCDGF ） and investigate the possibility of practicing endocrine therapy in estrogen receptor negative breast cancer. Methods Expression level of PCDGF mRNA was detected by fluorescence quantitative polymerase chain reaction and cell growth curve was drawn by cell count kit-8 method, then analyzed the relationship between the expression of PCDGF and dependence of estrogen. PCDGF shRNA vector was contructed and transfected into breast cancer cell lines （MCF-7 and MDA-MB-231 ） using Lipefectamin 2000, examined and compared the changes of estrogen dependence between the two cell lines. Results PCDGF was expressed in most breast cancer cell lines, and the growth dependence of estrogen was higher in the cells with high-expressing PCDGF than those with lowexpressing PCDGE Expression of PCDGF could be inhibited by transfected shRNA into MCF-7 and MDA- MB-231（inhibition rates were 81.1% and 86. 7% respectively）, inhibition of the expression of PCDGF could lead to higher growth dependence of estrogen, and the dependence of MDA-MB-231 was increased much more than MCF-7 （ P 〈 0. 05）. Conclusions The expression level of PCDGF is higher in estrogen receptor negative breast cancer than in estrogen receptor positive breast cancer. Inhibiting the expression of PCDGF could reverse resistance of endocrine therapy especially to estrogen receptor negative breast cancer.

作者石岚宋海平刘春萍黄韬

机构地区华中科技大学附属协和医院乳腺甲状腺外科中心

出处《中华外科杂志》 CAS CSCD 北大核心 2007年第7期483-486,共4页 Chinese Journal of Surgery

基金湖北省科技攻关重点基金(2006AA301 A05)

关键词乳腺肿瘤受体雌激素内分泌治疗 Breast neoplasms Receptors,estrogen Endocrine therapy

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献9

1Lu R, Serrero G. Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF cDNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468. Proc Natl Acad Sci U S A,2000,97:3993-3998.
2Tangkeangsirisin W, Hayashi J, Serrero G. PC cell-derived growth factor mediates tamoxifen resistance and promotes tumor growth of human breast cancer cells. Cancer Res ,2004,64 : 1737-1743.
3Tangkeangsirisin W, Serrero G. PC cell-derived growth factor ( PCDGF/GP88, progranulin ) stimulates migration, invasiveness and VEGF expression in breast cancer cells. Carcinogenesis,2004,25 : 1587-1592.
4Santen R J, Song RX, Zhang Z, et al. Adaptive hypersensitivity to estrogen:mechanism for sequential responses to hormonal therapy in breast cancer. Clinl Cancer Res,2004,10:337S-345S.
5Susan G, Hilsenbeckand C, Kent O. Is there a role for adjuvant tamoxifenin progesterone receptor positive breast cancer? An in silico clinical trial. Clin Cancer Res,2006,12:1049-1055.
6Bureombe B.l, Makris A, Richman PI, et al. Evaluation of ER,PgR,HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer ,2005,92:147-155.
7Nicholson RI, Staka C, Boyns F, et al. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr Relat Cancer,2004,11:623-641.
8唐波,姜军,彭志红.5氮2脱氧胞苷与三苯氧胺协同抗雌激素受体Α阴性乳腺癌的体外实验研究[J].中华外科杂志,2005,43(23):1545-1549. 被引量：5
9Yang X, Phillips DL, Ferguson AT, et al. Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Res,2001,61:7025-7029.